行情

EDIT

EDIT

Editas Medicine
NASDAQ

实时行情|Nasdaq Last Sale

31.57
+2.21
+7.53%
盘后: 31.90 +0.33 +1.05% 18:29 08/03 EDT
开盘
29.91
昨收
29.36
最高
31.98
最低
29.50
成交量
111.47万
成交额
--
52周最高
36.78
52周最低
14.01
市值
19.33亿
市盈率(TTM)
-11.4202
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EDIT价格均价为38.88,最高价位55.00,最低价为27.00。

EPS

EDIT 新闻

更多
Editas Medicine Option Alert: Aug 21 $45 Calls at the Ask: 1171 @ $0.3 vs 11933 OI; Earnings 8/6 After Close Ref=$30.4135
Benzinga · 9小时前
Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to Decline
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4天前
Editas taps Catalent to supply lineup of products
Seeking Alpha · 5天前
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
CAMBRIDGE, Mass. and SOMERSET, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions
GlobeNewswire · 5天前
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now
MotleyFool.com · 07/26 12:10
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Barrons.com · 07/25 15:52
Could Editas Medicine Be a Millionaire-Maker Stock?
CRISPR gene editing became a big story around 2012, and in the few years that followed, the promise of the technology spurred the founding of several biotechs focused on using it to treat diseases. Editas Medicine (NASDAQ: EDIT) was one of them. Since its IP
Motley Fool · 07/25 11:03
Is CRISPR Therapeutics Stock a Buy?
MotleyFool.com · 07/25 10:45

所属板块

生物技术和医学研究
+3.60%
制药与医学研究
+2.08%

热门股票

代码
价格
涨跌幅

EDIT 简况

Editas Medicine, Inc.(原名:Gengine,Inc.)是一家基因组编辑公司。该公司通过修正致病基因治疗遗传疾病。它通过开发和商业化基因组编辑技术部门运营。它正在开发1个基于成簇的规律间隔短回文重复序列(CRISPR)/CRISPR关联蛋白9(Cas9)技术的基因组编辑平台。CRISPR/Cas9将由Cas9酶组成的蛋白质核糖核酸(RNA)复合物和指导RNA分子结合,用于识别需要修复的特定脱氧核糖核酸(DNA)序列。该公司已经在多个治疗领域开展一系列研究项目。其研究项目包括眼科疾病、免疫肿瘤学工程T细胞疗法和其他研究项目,包括非恶性血液病、杜氏肌营养不良、囊性纤维化和α-1抗胰蛋白酶缺乏。
展开

微牛提供Editas Medicine Inc(NASDAQ-EDIT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EDIT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易EDIT股票基本功能。